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Summary
We present a case of a 14-year-old girl who was 
diagnosed with Burkitt lymphoma in 2014. she was 
managed with chemotherapy and remained in remission 
for 3 years. on her surveillance imaging in 2017, a left-
sided renal neoplastic mass was incidentally discovered. 
she underwent nephrectomy and pathology of the 
resected specimen revealed small cell tumour of the 
kidney with features favouring renal ewing sarcoma/
primitive neuroectodermal tumour. Molecular genetic 
analysis by fluorescence in situ hybridisation was 
performed which showed translocation of 22q12, 
thereby confirming the diagnosis. this is a rare secondary 
malignancy and an unusual association. this case 
highlights the importance and diagnostic dilemmas 
of rare secondary tumours in patients with such 
haematological malignancies and discusses its possible 
pathogenetic aspects.
BaCkground 
The metachronous development of secondary 
malignancies of a different histological type 
and at a different location has always been a 
subject of concern in cancer survivors. Attribut-
able factors include those linked to the tumour 
itself, genetic makeup of the patient, pre-existing 
conditions and most importantly therapy-related 
interventions. Most often, secondary malignan-
cies can be linked to the long-lasting cytotoxic 
effects of radiotherapy, chemotherapy, immuno-
therapy and endocrine therapy. However, the 
exact underlying mechanism of tumorigenesis 
in such instances remains uncertain. Generally, 
non-random somatic molecular or chromosomal 
modifications are implicated in the development 
of secondary cancers.1 
Secondary malignancies are frequently found 
in those who have had a primary haematological 
malignancy in childhood. Surveillance of secondary 
malignancy may be especially important in patients 
with Burkitt lymphoma (BL) considering its high 
curability rate and the intensity of treatment; 
however, the exact rate of development of meta-
chronous cancers in such patients is unknown. 
Recently, we diagnosed a case of renal Ewing 
sarcoma (ES)/primitive neuroectodermal tumour 
(PNET) that was incidentally discovered during 
regular surveillance imaging in a survivor of BL. 
This is an unusual occurrence and there have been 
no reported cases of metachronous renal ES/PNET 
in patients with such haematological malignancies.
CaSe preSenTaTion
A 14-year-old girl presented with abdominal disten-
sion and abdominal pain in 2014. She had no signifi-
cant medical or surgical history. She underwent a CT 
scan and was suspected to have a lymphoprolifera-
tive disorder with abdominal manifestations (ascites, 
omental thickening and nodularity) (figure 1). Ascitic 
fluid analysis, omental deposit histopathology and 
bone marrow biopsy along with immunochemical and 
genetic analysis confirmed the diagnosis of BL with 
positive t(8; 14) translocation. She was diagnosed 
as stage III and central nervous system negative, and 
treated based on FAB/LMB96 protocol with COP/
Figure 1 CT scan in 2014 showing gross ascites and extensive omental thickening with peritoneal nodularity. The 
diagnosis based on ascitic fluid analysis and omental and bone marrow biopsy along with immunochemistry and 
genetic analysis was Burkitt lymphoma.
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COPADM 1, 2 and CYM 1, 2 chemotherapy cycles (table 1) which 
included vincristine, methotrexate, doxorubicin and cyclophospha-
mide, and she went into complete remission within 3 months of 
therapy (figure 2).
Routine follow-up imaging in 2017 revealed a large hetero-
geneous neoplastic mass with areas of necrosis arising from the 
lower pole of the left kidney, measuring 7×6×8 cm (figure 3). 
There was no associated lymphadenopathy or metastatic 
disease. A left nephroureterectomy was done. Intraoperative 
findings showed a large tumour in the lower pole of the kidney. 
The mesocolon and descending colon were adherent over the 
tumour, but were separated. No peritoneal deposits or enlarged 
lymph nodes were found.
inveSTigaTionS
Histopathology revealed a solid, cystic, haemorrhagic renal 
lesion. Sections examined showed uniform population of 
small-to-intermediate-sized cells arranged in sheets and rosettes. 
The neoplastic cells had round to slightly irregular, hyperchro-
matic nuclei and scant cytoplasm. Intervening areas showed 
haemorrhagic spaces filled with blood. Special stain (PAS+/-D) 
highlighted focal cytoplasmic glycogen. Immunohistochemical 
stains were performed and the tumour cells showed strong, 
diffuse, membranous staining for CD99 (MIC 2) immunostains 
(figure 4). Tumour cells were also positive for cyclin D1 and 
BCL-2 immunostains. Cytokeratin AE1/AE3, EMA, desmin and 
WT1 were negative (table 1). The renal capsule and right ureter 
were tumour free. The final diagnosis was small round blue 
cell tumour (SRBCT) with features favouring renal ES/PNET. 
Molecular genetic analysis by fluorescence in situ hybridisation 
(FISH) was performed which showed translocation of 22q12, 
thereby confirming the diagnosis.
ouTCome and Follow-up
Postoperatively, the child remained stable. She has been started 
on chemotherapy based on the COG Ewing’s protocol with 
alternating cycles of VDC/IE and is presently doing well.
diSCuSSion
BL is a subtype of non-Hodgkin's lymphoma with an incidence 
of about 0.4 cases per 100 000. BL is managed with recently 
updated high-intensity, short-duration combination chemo-
therapy. Treatment is most often curative with approximately 
90% of paediatric patients obtaining long-term remission.2 
Therefore, development of a second malignancy in such survi-
vors has always remained an important concern.3 The rate 
of development of secondary tumours can be as high as 21% 
according to previous reports and the latent period between 
the developments of two neoplasms is also variable.4 The most 
frequently reported secondary malignancies in this subset of 
patients include cancers of the head and neck, lung, colon, 
bladder, kidney, melanoma, thyroid, leukaemias and various 
sarcomas such as Kaposi sarcoma.5
The rate of secondary malignancies in patients with BL is 
unknown, and the probability is found to be higher in other forms 
of non-Hodgkin's lymphoma such as lymphoblastic lymphoma 
or large-cell lymphoma. There are only few reports on ES as a 
secondary malignancy and most reported cases comprise single 
case reports or series following therapy for leukaemias, Wilms 
tumour (WT), neuroblastoma, retinoblastoma or germ cell 
tumours. These secondary ES tumours have primarily involved 
Table 1 Abbreviations key
Bl Burkitt lymphoma
ES Ewing sarcoma
PNET Primitive neuroectodermal tumour
CNS Central nervous system










CD99 (MIC2) Cluster of differentiation 99
BCL-2 B-cell lymphoma 2
EMA Epithelial membrane antigen
WT1 Wilms tumor-1
FISH Fluorescence in situ hybridisation






SRBCT Small round blue cell tumour
EWSR1 Ewing sarcoma breakpoint region 1
ETS Erythroblast transformation-specific
FLI1 Friend leukaemia integration 1 transcription factor
RT-PCR Reverse transcription PCR
Figure 2 Within 3 months of high-intensity chemotherapy, there was complete remission of the disease.
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sites such as the ribs, chest wall, soft tissues, pelvis and extrem-
ities and do not appear to be related to radiotherapy.6–9 An 
unusual case of ES of the adrenal gland is the only documented 
case of secondary ES in a survivor of BL.10 Renal ES/PNET is 
an extremely rare and aggressive SRBCT, affecting adolescents 
and young adults. This tumour has an incidence of about 1 in 
1 000 000 with a male to female ratio of 1.5:1. Less than 100 
cases have been reported to date globally.11
Cytogenetic features of renal ES/PNET include fusion of the 
EWSR1 gene with a member of the ETS family of oncogenes, 
arising at a specific chromosomal translocation. More than 
90% of these are reciprocal translocations t (11;22) (q24;q12), 
resulting in an EWSR1/FLI1 fusion transcript.12 In ES as a 
secondary malignancy, it is advocated that antitumour activity of 
the innate or adaptive immune system may get impaired, there-
fore causing dysfunction and inability of the system to identify 
and eradicate the newly mutated cells carrying the ES translo-
cation, therefore initiating the development of secondary ES.1 
Our patient received intensive chemotherapy for BL and because 
of the relatively short latent period of occurrence of this malig-
nancy (3 years), the previous exposure to doxorubicin might be 
implicated with development of secondary ES. This is because 
topoisomerase II inhibitor-associated secondary malignancies 
have relatively shorter latent periods than those associated with 
alkylating agents.10
Histologically, it can be challenging to differentiate 
renal ES from other SRBCTs, synovial sarcoma, malignant 
lymphoma, WT, neuroblastoma and small cell neuroendo-
crine tumour because these tumours often show overlapping 
cytomorphological features.13 Therefore, immunocytochem-
istry and detection of the translocation by FISH or RT-PCR 
techniques have always been critical in reaching the diag-
nosis. The basis of diagnosis of our case as renal ES/PNET 
were histomorphology of SRBCT, immunohistochemical posi-
tivity of CD99 and presence of EWSR1 gene rearrangement. 
This molecular signature is typical for the PNET as well. In the 
current WHO classification, PNET which was once believed to 
be a separate disease is now included as part of the histological 
spectrum of the ‘Ewing family of tumours’.14
The radiographic features of renal ES/PNET are non-spe-
cific and almost indistinguishable from renal cell carcinoma. 
Figure 3 Surveillance CT imaging in 2017 revealing a large heterogeneous neoplastic lesion with areas of necrosis arising from the lower pole 
of left kidney. There was no lymphadenopathy or metastatic disease. This proved to be renal Ewing sarcoma/primitive neuroectodermal tumour on 
pathology.
Figure 4 (A) The renal lesion was composed of uniform population of basophilic cells arranged in sheets and rosettes. (B) The neoplastic cells had 
round to slightly irregular, hyperchromatic nuclei and scant cytoplasm. (C) Immunohistochemical stains were performed which showed positive CD99.
learning points
 ► It is vital to understand the potential of development 
of secondary malignancies, both treatment-related and 
associated with the genetic background of patients with 
cancer because their survival will continue to improve in the 
near future due to substantial improvements in multimodal 
therapy regimens.
 ► It is essential to distinguish primary renal Ewing 
sarcoma from the other small blue round cell tumours 
by immunohistochemical and genetic methods because 
radiological and histological features often overlap, and 
differentiation is essential for deciding the right choice of 
treatment.
 ► In the absence of molecular genetic analysis in poor 
socioeconomic conditions, careful histopathological and 
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Features in previously published reports include large masses 
of heterogeneous architecture with areas of internal haemor-
rhage and necrosis, but no signs of extensive parenchymal or 
hilar infiltration.15
The primary treatment strategy is surgical resection with 
adjuvant chemotherapy. The role of radiotherapy is uncertain 
but nonetheless has been used to treat local tumour progres-
sion; however, no randomised clinical trials are available to 
validate this because of the rarity of renal ES/PNET. Adjuvant 
chemotherapy regimens have included vincristine, doxoru-
bicin, cyclophosphamide, ifosfamide and etoposide, but the 
combination of drugs used has varied broadly among different 
centres.16 Renal ES/PNET usually shows a poor prognosis with 
recurrence and metastases comprising more than 50% of clin-
ical presentations. In a recent review of 26 cases, the mean 
patient survival was approximately 10 months.17 The fact that 
the tumour was incidentally discovered in our patient who had 
no regional or metastatic disease is noteworthy. Therefore, 
accurate diagnostic measures, such as imaging, biopsy and 
histopathology are crucial for timely management.12
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